ALTHOUGH UNCOMMON, MENINGOCOCCAL DISEASE MOVES FAST AND IS POTENTIALLY FATAL"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"9
Serogroup B caused almost 1/3 of all US meningococcal cases in patients aged <1 to ≥65 years, from 2005-2014; N=867"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"15
ACIP recommendation for MenB vaccination
ACIP recommends that patients 16-23 years of age may be vaccinated against MenB, preferably between ages 16-18."scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"16
|ACIP=Advisory Committee on Immunization Practices.|
|*||Includes serogroup W-135 and serogroups unable to be identified.|
BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals 10 through 25 years of age.
Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.